 |
 Video: What is a Stock Split?
|
|
|
| MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is vobramitamab duocarmazine, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia. According to our MacroGenics stock split history records, MacroGenics has had 0 splits. | |
|
MacroGenics (MGNX) has 0 splits in our MacroGenics stock split history database.
Looking at the MacroGenics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into MacroGenics shares, starting with a $10,000 purchase of MGNX, presented on a split-history-adjusted basis factoring in the complete MacroGenics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/25/2014 |
|
| End date: |
04/23/2024 |
|
| Start price/share: |
$20.54 |
|
| End price/share: |
$16.23 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-20.98% |
|
| Average Annual Total Return: |
-2.33% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$7,899.21 |
|
| Years: |
10.00 |
|
|
|
|
|
